**Table 4:**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Variable | Total AI, N = 31 | PAI, N = 7 | SAI, N = 24 | p-value | AI, N = 31 | No-AI, N = 400 | p-value |
| Age at enrolment, median (IQR) years | 36 (32, 46) | 40 (35, 45) | 36 (31, 45) | 0.6 | 36 (32, 46) | 36 (31, 42) | 0.3 |
| Female-gender, n (%) | 16 (51.6%) | 3 (42.9%) | 13 (54.2%) | 0.7 | 16 (51.6%) | 202 (50.8%) | >0.9 |
| Ethnicity, n (%) |  |  |  | 0.5 |  |  | 0.3 |
| Black African | 28 (90.3%) | 6 (85.7%) | 22 (91.7%) |  | 28 (90.3%) | 329 (82.9%) |  |
| Other | 3 (9.7%) | 1 (14.3%) | 2 (8.3%) |  | 3 (9.7%) | 68 (17.1%) |  |
| Duration of current illness, median (IQR) days | 14 (14, 30) | 10 (7, 12) | 21 (14, 30) | 0.012 | 14 (14, 30) | 14 (14, 21) | 0.4 |
| Random morning cortisol, median (IQR) nmol/L | 258 (210, 370) | 344 (267, 390) | 256 (193, 345) | 0.2 | 258 (210, 370) | 486 (388, 582) | <0.001 |
| Basal cortisol, median (IQR) nnol/L | 300 (209, 368) | 315 (214, 327) | 300 (210, 378) | 0.6 | 300 (209, 368) | 473 (368, 580) | <0.001 |
| Stimulated cortisol, median (IQR) nmo/L | 420 (338, 473) | 403 (363, 435) | 421 (326, 478) | 0.6 | 420 (338, 473) | 727 (640, 859) | <0.001 |
| ACTH, median (IQR) pmol/L | 25 (14, 56) | 144 (80, 158) | 23 (12, 29) | <0.001 | 25 (14, 56) | 32 (21, 51) | 0.5 |
| BP (systolic), median (IQR) mmHg | 120 (102, 128) | 120 (120, 124) | 115 (100, 128) | 0.5 | 120 (102, 128) | 110 (100, 124) | 0.4 |
| BP (diastolic), median (IQR) mmHg | 71 (62, 80) | 70 (70, 82) | 71 (60, 78) | 0.7 | 71 (62, 80) | 69 (60, 77) | 0.074 |
| Postural drop in blood pressure | 2 (6.5%) | 0 (0.0%) | 2 (8.3%) | >0.9 | 2 (6.5%) | 12 (3.2%) | 0.3 |
| Heart rate, median (IQR) bpm | 86 (78, 108) | 97 (88, 111) | 85 (77, 107) | 0.11 | 86 (78, 108) | 92 (81, 110) | 0.4 |
| Hypotension, n (%) | 1 (3.2%) | 0 (0.0%) | 1 (4.2%) | >0.9 | 1 (3.2%) | 29 (7.7%) | 0.7 |
| Weakness, n (%) | 25 (80.6%) | 4 (57.1%) | 21 (87.5%) | 0.11 | 25 (80.6%) | 318 (83.9%) | 0.6 |
| Tiredness, n (%) | 27 (87.1%) | 5 (71.4%) | 22 (91.7%) | 0.2 | 27 (87.1%) | 322 (84.7%) | >0.9 |
| Poor appetite, n (%) | 26 (83.9%) | 6 (85.7%) | 20 (83.3%) | >0.9 | 26 (83.9%) | 281 (74.5%) | 0.2 |
| Weight loss, n (%) | 25 (80.6%) | 7 (100.0%) | 18 (75.0%) | 0.3 | 25 (80.6%) | 338 (88.7%) | 0.2 |
| Increased pigmentation of the skin, n (%) | 11 (39.3%) | 3 (60.0%) | 8 (34.8%) | 0.4 | 11 (39.3%) | 169 (46.0%) | 0.5 |
| Nausea, n (%) | 18 (58.1%) | 5 (71.4%) | 13 (54.2%) | 0.7 | 18 (58.1%) | 191 (50.4%) | 0.4 |
| Vomiting, n (%) | 8 (25.8%) | 4 (57.1%) | 4 (16.7%) | 0.053 | 8 (25.8%) | 104 (27.5%) | 0.8 |
| Liking for salt, n (%) | 21 (67.7%) | 5 (71.4%) | 16 (66.7%) | >0.9 | 21 (67.7%) | 235 (62.5%) | 0.6 |
| Hypoglycaemia, n (%) | 31 (100.0%) | 0 | 0 |  | 0 (0.0%) | 9 (2.4%) | >0.9 |
| Loss of consciousness, n (%) | 30 (100.0%) | 0 | 0 |  | 0 (0.0%) | 5 (1.3%) | >0.9 |
| Diarrhea, n (%) | 9 (29.0%) | 1 (14.3%) | 8 (33.3%) | 0.6 | 9 (29.0%) | 153 (40.7%) | 0.2 |
| Dizziness, n (%) | 14 (46.7%) | 4 (66.7%) | 10 (41.7%) | 0.4 | 14 (46.7%) | 165 (43.8%) | 0.8 |
| Shock, n (%) | 31 (100.0%) | 0 | 0 | \_ | 0 (0.0%) | 5 (1.3%) | >0.9 |
| Anorexia, n (%) | 9 (29.0%) | 4 (57.1%) | 5 (20.8%) | 0.2 | 9 (29.0%) | 163 (43.1%) | 0.13 |
| Loss of axillary and pubic hair in females, n (%) | 3 (10.0%) | 1 (14.3%) | 2 (8.7%) | 0.6 | 3 (10.0%) | 65 (16.9%) | 0.6 |
| Presence of anaemia, n (%) | 15 (50.0%) | 4 (57.1%) | 11 (47.8%) | >0.9 | 15 (50.0%) | 208 (55.3%) | 0.6 |
| Presence of an opportunistic infection, n (%) | 31 (100.0%) | 7 (100.0%) | 24 (100.0%) |  | 31 (100.0%) | 393 (99.0%) | >0.9 |
| Viral load, median (IQR) (log10 Copies/mL) | 4.79 (4.07, 5.19) | 5.04 (5.04, 5.04) | 4.54 (3.61, 5.09) | >0.9 | 4.79 (4.07, 5.19) | 4.40 (3.16, 5.35) | 0.8 |
| Total CD4 count, median (IQR) | 39 (14, 50) | 46 (26, 61) | 35 (12, 50) | 0.3 | 39 (14, 50) | 31 (14, 60) | >0.9 |
| Sodium, median (IQR) mmol/L | 135.0 (132.5, 137.0) | 133.0 (131.5, 136.5) | 135.5 (133.8, 137.0) | 0.3 | 135.0 (132.5, 137.0) | 134.0 (130.0, 137.0) | 0.067 |
| Potassium, median (IQR) mmol/L | 3.90 (3.30, 4.35) | 3.60 (3.25, 3.85) | 3.95 (3.45, 4.52) | 0.3 | 3.90 (3.30, 4.35) | 4.10 (3.60, 4.60) | 0.12 |
| Haemoglobin, median (IQR) g/dL | 8.70 (7.80, 10.45) | 10.20 (7.85, 10.35) | 8.70 (7.85, 10.60) | 0.8 | 8.70 (7.80, 10.45) | 8.70 (7.40, 10.30) | 0.5 |
| White cell count, median (IQR) X109 | 5 (3, 7) | 4 (3, 5) | 5 (4, 11) | 0.3 | 5.2 (3.1, 7.0) | 5.4 (3.7, 8.1) | 0.7 |
| Lymphocyte count, median (IQR) X109 | 1 (1, 1) | 1 (1, 1) | 1 (0, 1) | 0.7 | 0.9 (0.5, 1.3) | 0.8 (0.3, 1.9) | 0.6 |
| Neutrophils, median (IQR) | 1.28 (0.95, 1.63) | 0.92 (0.92, 0.92) | 1.54 (1.02, 1.66) | 0.7 | 1 (1, 2) | 3 (1, 9) | 0.068 |
| Early Mortality, n (%) | 4 (28.6%) | 0 (0.0%) | 4 (36.4%) | 0.5 | 4 (28.6%) | 23 (16.3%) | 0.3 |
| Intermediate mortality, n (%) | 6 (40.0%) | 2 (50.0%) | 4 (36.4%) | >0.9 | 6 (40.0%) | 29 (19.3%) | 0.092 |
| Late mortality, n (%) | 7 (36.8%) | 2 (50.0%) | 5 (33.3%) | 0.6 | 7 (36.8%) | 37 (22.2%) | 0.2 |
| Tuberculosis, n (%) | 19 (61.3) | 4 (57.1%) | 15 (62.5%) | >0.9 | 19 (61.3%) | 294 (73.5%) | 0.14 |
| Cryptococcus neoformans, n (%) | 0 | 0 | 0 | >0.9 | 0 | 1 (0.3%) | > 0.9 |
| Cytomegalovirus, n (%) | 1 (3.2%) | 0 | 1 (4.2%) |  | 1 (3.2%) | 0 | 0.072 |
| Other opportunistic infections, n (%) | 13 (14.9%) | 3 (42.9%) | 10 (41.7%) | >0.9 | 13 (14.9%) | 101 (25.2%) | 0.042 |